Foamix Pharmaceuticals has entered into a long term contract manufacturing and supply agreement with ASM Aerosol-Service for the company’s recently approved AMZEEQ (minocycline) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and for its product candidate FMX103 (minocycline) topical foam, 1.5% for the potential treatment of moderate to severe papulopustular rosacea in adults. ASM...